Thumbnail Image

Anand Agricultural University, Anand

Anand Agricultural University (AAU) was established in 2004 at Anand with the support of the Government of Gujarat, Act No.(Guj 5 of 2004) dated April 29, 2004. Caved out of the erstwhile Gujarat Agricultural University (GAU), the dream institution of Sardar Vallabhbhai Patel and Dr. K. M. Munshi, the AAU was set up to provide support to the farming community in three facets namely education, research and extension activities in Agriculture, Horticulture Engineering, product Processing and Home Science. At present there seven Colleges, seventeen Research Centers and six Extension Education Institute working in nine districts of Gujarat namely Ahmedabad, Anand, Dahod, Kheda, Panchmahal, Vadodara, Mahisagar, Botad and Chhotaudepur AAU's activities have expanded to span newer commodity sectors such as soil health card, bio-diesel, medicinal plants apart from the mandatory ones like rice, maize, tobacco, vegetable crops, fruit crops, forage crops, animal breeding, nutrition and dairy products etc. the core of AAU's operating philosophy however, continues to create the partnership between the rural people and committed academic as the basic for sustainable rural development. In pursuing its various programmes AAU's overall mission is to promote sustainable growth and economic independence in rural society. AAU aims to do this through education, research and extension education. Thus, AAU works towards the empowerment of the farmers.

Browse

2009 - 200912010 - 20121
Reset filters
Subject: Veterinary Pharmacology and Toxicology × Author: SADARIYA, KAMLESH AMARSHIBHAI ×
Reset filters

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    ThesisItemOpen Access
    STUDIES ON EFFECT OF FEVER AND CO-ADMINISTRATION OF KETOPROFEN ON PHARMACOKINETICS OF MOXIFLOXACIN AND SAFETY OF SIMULTANEOUS ADMINISTRATION OF MOXIFLOXACIN AND KETOPROFEN IN SHEEP
    (AAU, Anand, 2012) SADARIYA, KAMLESH AMARSHIBHAI; Thaker, A. M.
    Moxifloxacin is a novel fourth generation fluoroquinolone with broad spectrum of antibacterial activity. The use of non-steroidal anti-inflammatory drugs (NS AIDs) is frequently recommended with antibacterials for the treatment of various bacterial infections accompanied by fever and other inflammatory conditions in animals. Ketoprofen (KTP) is an aryl propionic acid derivative, non-selective COX inhibitor NSAID having anti-inflammatory, analgesic and antipyretic properties. In veterinary practice, ketoprofen is used to lower body temperature in animals having fever, to reUeve bacteremia and pain in all animals. Pharmacokinetics of an antibacterial drug may change when administered with anti-inflammatory drug or in febrile animals. Despite the great potential for clinical use of moxifloxacin in India, the data on its pharmacokinetics and safety profile in sheep are scarce. Moxifloxacin was assayed in plasma by HPLC. The present study was planned to determine the effect of intramuscularly administered ketoprofen (3 mg/kg) and lipopolysaccharide (LPS) induced febrile condition on pharmacokinetics of moxifloxacin following intravenous and intramuscular administration (5 mg/kg) in sheep and safety of daily intramuscular administration of moxifloxacin (3 mg/kg) in combination with intramuscular administration of Icetoprofen (3 mg/kg) for five days in sheep by monitoring haematological and serum biochemical profiles. Following intravenous administration of moxifloxacin in normal healthy sheep, the plasma drug concentration > 0.17 ± 0.01 μg/ml was detected up to 12 h, while plasma drug concentration > 0.13 ±0.01 μg/ml was detected up to 18 h in ketoprofen treated and febrile sheep. The plasma drug concentrations in the present study were consistently higher in ketoprofen treated and febrile group than in normal sheep. Following intravenous administration of moxifloxacin in normal sheep, the mean distribution half-life (t1/2α), apparent volume of distribution (Vdarea), volume of distribution at steady-state (Vdss), area under plasma drug concentration-time curve (AUC0-∞), area under first moment curve (AUMC), elimination half-life (t1/2β), total body clearance (CIB) and mean residence time (MRT) were 3.55 ± 0.56 h, 4.88 ± 0.20 L/kg, 3.49 ± 0.11 L/kg, 8.38 ± 0.23 μg.h/mL, 49.52 ± 3.83 μg.h2/mL, 5.70 ± 0.37 h, 0.60 ± 0.02 L/h/kg and 5.87 + 0.32 h, respectively. Following intravenous administration of moxifloxacin in ketoprofen-treated sheep, the mean distribution half-life (t1/2α), apparent volume of distribution (Vdarea) and volume of distribution at steady-state (Vdss) were 2.63 ± 0.42 h, 1.67 ± 0.09 and 1.37 ± 0.02 L/kg, respectively. The elimination half-life (t1/2β), total body clearance (CIB) and mean residence time (MRT) were 4.08 ± 0.25 h, 0.29 ± 0.01 L/h/kg and 4.79 ± 0.07 h, respectively. The average values for area under plasma drug concentrationtime curve (AUC0-∞) and area under first moment curve (AUMC) were 17.55 ± 0.25 μg.h/mL and 84.14 + 1.96 μgh2/mL, respectively. Significant alterations in pharmacokinetic parameters in ketoprofen-treated and febrile sheep have been observed compared to normal sheep. Following intravenous administration of moxifloxacin in ketoprofen-treated sheep, a significant increase in mean value of various pharmacokinetic parameters like Cp0, A, B, p, AUC(0-∞) and AUMC were observed as compared to respective pharmacokinetic parameters of moxifloxacin in normal sheep. However, significant decrease in mean values of t1/2β, Vd(area), Vd(ss), C1(B) and MRT in ketoprofen treated group as compare to normal healthy sheep. In febrile sheep, the AUC (14.88 ± 0.39 μg.h/mL) and AUMC (88.82 ± 4.38 μg.h2/mL) were significantly (p<0.01) increased following intravenous administration of moxifloxacin. Significant (p<0.01) decrease in mean values of distribution half-life (t1/2α: 0.25 ± 0.03 h), total body clearance (CIB) (0.34 ± 0.01 L/h/kg), volume of distribution (Vdarea: 2.76 ± 0.04 L/kg) and volume of distribution at steady state (Vdss. 2.00 ± 0.03 L/kg) of the drug was observed in febrile compared to respective pharmacokinetic parameters in normal sheep.
  • Thumbnail Image
    ThesisItemOpen Access
    STUDIES ON PHARMACOKINETIC INTERACTION OF MOXIFLOXACIN AND MELOXICAM AND SAFETY OF MOXIFLOXACIN IN WISTAR RATS
    (AAU, Anand, 2009) SADARIYA, KAMLESH AMARSHIBHAI; BHAVSAR, S. K.
    Antibacterial are frequently recommended as an adjunct therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) to treat various bacterial infections accompanied by fever and other inflammatory conditions in animals. Moxifloxacin is a novel fourth generation fluoroquinolone with broad spectrum of antibacterial activity. Meloxicam is a member of the oxicam family of NSAIDs having antiinflammatory, analgesic and antipyretic properties. The pharmacokinetic of Moxifloxacin (5.0 mg/kg) and Meloxicam (0.5 mg/kg) as single drug and in combination after its intramuscular administration was investigated in 36 male and female wistar rats. Moxifloxacin and Meloxicam were assayed in plasma by HPLC. Pharmacokinetic parameters were calculated by non-compartmental technique using computer software (WinNonlin, version 5.0.1). The present study also evaluated safety of Moxifloxacin (5.0 mg/kg) after repeated administration at 24 h interval for 14 days in 24 male and female Wistar rats. The mean peak plasma concentration (Cmax) of Moxifloxacin following its administration as single drug and in combination with Meloxicam in male rats were 301.41 ± 25.07 and 375.72 ± 44.97 ng/ml respectively, which was observed at 1 h. while in female rats mean Cmax of moxifloxacin were 251.43 ± 46.36 and 152.95 ± 4.45 ng/ml respectively, which was observed at 0.67 and 1 h respectively. The mean peak plasma concentration (Cmax) of Meloxicam following its administration as single drug and in combination with Moxifloxacin were 2539.67 ± 160.01 and 1859.01 ± 219.92 ng/ml respectively, in male rats. The mean Cmax values of Meloxicam in female rats were 2018.73 ± 128.52 and 2339.33 ± 149.00 ng/ml respectively, which was observed at 2 h. Peak plasma concentration (Cmax) Meloxicam was significantly lower in male rats following concurrent intramuscular administration of Moxifloxacin and Meloxicam. Following intramuscular administration of Moxifloxacin(5.0 mg/kg) as single drug and in combination with Meloxicam (0.5 mg/kg) in male wistar rats the mean values of half-life (t 1/2), volume of distribution (Vz), clearance (CI) and area under plasma drug concentration-time curve (AUC (o-α)) of Moxifloxacin were 2.27 ± 0.14 and 1.98 ± 0.31 hr, 11051.18 ± 530.11 and 9728.50 ± 1533.39 ml, 3442.16 ± 255.67 and 3632.24 ± 700.00 ml/hr and 1496.67 ± 120.04 and 1575.18 ± 222.45 hr.ng/ml, respectively. Whereas in female rats mean values of Moxifloxacin were 1.95 ± 0.22 and 3.56 ± 0.95 hr, 19526.48 ± 3171.76 and 36868.52 ± 6032.37 ml, 6005.43 ± 1134.19 and 5974.10 ± 1108.59 ml/hr and 1076.79 ± 282.55 and 1028.86 ± 218.83 hr.ng/ml, respectively. Volume of distribution (Vz) was significantly higher in female rats following concurrent intramuscular administration of Moxifloxacin and Meloxicam.